About Cocrystal Pharma
Developing and Commercializing Novel Small-Molecule Antiviral Drugs Using Proprietary Breakthrough Technologies
Cocrystal Pharma, Inc. is a pharmaceutical company with a mission to discover novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. Utilizing our unique nucleoside chemistry and Nobel Prize winning expertise, we create first- and best-in-class antiviral drugs. These technologies and our market-focused approach to drug discovery are designed to efficiently deliver small molecule therapeutics that are safe, effective and convenient to administer.
Employing Nobel Prize Winning Expertise
Our award-winning team includes three industry leaders: Dr. Roger Kornberg (Founder and Chief Scientist), Raymond F. Schinazi (Founder and Chairman of our Board of Directors) and Phillip Frost (member of our Board of Directors).
Teaming up with a Highly Successful Investment Group
Major investors include private investment firms, publicly traded healthcare/pharmaceutical companies and individuals.
Partnerships & Licensing
The antiviral drug market and our technology are creating attractive partnership and M&A opportunities with pharmaceutical companies.
We are always looking for talented individuals to join our team.